Skip to content
Wockhardt
  • Home
  • About Us
    • Chairman’s Profile
    • Board Of Directors
    • Team Wockhardt
    • Corporate Milestones
    • Research & Development
      • R&D at Wockhardt
      • New Drug Discovery
        • Pipeline / Projects
        • News & Events
        • Publications
          • ZAYNICH®
          • WCK 4873
          • WCK 4282
          • WCK 6777
      • Biologicals
        • News & Events
        • Pipeline / Projects
        • Publications
      • R&D Contact
    • Our Manufacturing Units
      • Shendra, India
      • Biotech Park, India
      • Daman, India
      • Ankleshwar, India
    • Global Footprint
      • India
      • UK & Europe
      • Emerging Markets
    • Products
      • India Branded Business
      • API
      • Russia – CIS
      • UK
      • Irish Market
      • Emerging Markets
      • Quality Generics
    • Quality Policy
  • Investors
    • From Chairman’s Office
      • AGM Speech
      • Letter to Shareowners
    • Financials
      • Annual Report
      • Quarterly Results
      • Financial Press Releases
      • Related Party Transactions
    • Subsidiary Financials
    • Annual Return
    • Corporate Governance
      • Policies & Codes
      • Committee’s of the Board
      • Familiarisation programs
      • Shareholding Pattern
      • Secretarial Compliance Report
      • Authorised KMP
      • Corporate Actions
      • Memorandum of Association and Article of Association
      • ESOP Scheme
      • Disclosures under Regulation 46 of SEBI LODR Regulations
    • Announcements / Disclosures
    • Shareholders Meeting / Postal ballot
      • AGM Notice
      • Proceedings
      • Voting Results
      • Transcript of the AGM
    • IEPF
      • Unclaimed Dividend
      • Nodal Officer
    • Analyst/ Investors
      • Presentation
      • Audio / Video Recording
      • Transcript
    • Shareowner Services
      • FAQ
      • Green Initiative
      • Investor Contact
      • Other Notices
      • Credit Rating
  • careers
    • Introduction
    • Life@Wockhardt
    • L&D Initiatives
    • Voice of Wockhardians
    • Career@Wockhardt
  • Media
    • Press Releases
    • Wockhardt in Media
  • ESG
  • Contact us

Home / 2012-2013 / Page 2

PDF Year: 2012-2013

FINANCIAL RESULTS FY13 Q3

Chairman’s letter to shareowners Q2 2012 – 13

FINANCIAL RESULTS FY 2012 – 13 Q2 JUL – SEP 2012)

FINANCIAL RESULTS FY18 Q2

WOCKHARDT LAUNCHES GENERIC VERSION OF ANTI – ULCER DRUG PREVACID®

WOCKHARDT LAUNCHES GENERIC VERSION OF ANTIDEPRESSANT DRUG WELLBUTRIN® SR

WOCKHARDT RECEIVES US FDA APPROVAL FOR GENERIC VERSION OF PARKINSONISM DRUG REQUIP XL®

WOCKHARDT RECEIVES TENTATIVE US FDA APPROVAL FOR GENERIC VERSION OF ANTI – PSYCHOTIC DRUG GECDON®

WOCKHARDT TO LAUNCH GENERIC VERSION OF ANTI – HYPERTENSIVE DRUG PLENDIL®

WOCKHARDT RECEIVES US FDA APPROVAL FOR GENERIC VERSION OF PARKINSON’S DRUG COMTAN®

Posts navigation

Previous page Page 1 Page 2 Page 3 Page 4 Next page

Recent Posts

  • Home

Recent Comments

  • A WordPress Commenter on Home

Archives

  • June 2018

Categories

  • account of subs
  • AGM
  • AGM Notice
  • Analyst / Investors
  • Announcements or Disclosures
  • annual reports
  • Annual Return
  • Attendance slip
  • Audio Video Recording
  • Chairman_s Agm Speeches
  • Chairman_s Letter
  • Committee's of the Board
  • Corporate Actions
  • Credit Rating
  • Details of Unclaimed Dvidends
  • Familiarisation programs
  • FAQ
  • Filing with Stock Exchange
  • Financial Press Releases
  • Financials at a glance
  • Investor Communication
  • Investor Meet
  • Media Coverage
  • Newspaper AD
  • Other Shareholder Services
  • Policies
  • Presentation
  • Press Release
  • Proceedings
  • Quarterly Reports
  • Relater Party Transactions
  • Secretarial Compliance Report
  • Shareholding Pattern
  • Statutory Communication
  • Subsidiary Financials
  • Transcript
  • Transcript of the AGM
  • Transfer of Shares to IEPF
  • Uncategorized
  • Voting Results

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Home
  • About Us
    • Chairman’s Profile
    • Board Of Directors
    • Team Wockhardt
    • Corporate Milestones
    • Research & Development
      • R&D at Wockhardt
      • New Drug Discovery
        • Pipeline / Projects
        • News & Events
        • Publications
          • ZAYNICH®
          • WCK 4873
          • WCK 4282
          • WCK 6777
      • Biologicals
        • News & Events
        • Pipeline / Projects
        • Publications
      • R&D Contact
    • Our Manufacturing Units
      • Shendra, India
      • Biotech Park, India
      • Daman, India
      • Ankleshwar, India
    • Global Footprint
      • India
      • UK & Europe
      • Emerging Markets
    • Products
      • India Branded Business
      • API
      • Russia – CIS
      • UK
      • Irish Market
      • Emerging Markets
      • Quality Generics
    • Quality Policy
  • Investors
    • From Chairman’s Office
      • AGM Speech
      • Letter to Shareowners
    • Financials
      • Annual Report
      • Quarterly Results
      • Financial Press Releases
      • Related Party Transactions
    • Subsidiary Financials
    • Annual Return
    • Corporate Governance
      • Policies & Codes
      • Committee’s of the Board
      • Familiarisation programs
      • Shareholding Pattern
      • Secretarial Compliance Report
      • Authorised KMP
      • Corporate Actions
      • Memorandum of Association and Article of Association
      • ESOP Scheme
      • Disclosures under Regulation 46 of SEBI LODR Regulations
    • Announcements / Disclosures
    • Shareholders Meeting / Postal ballot
      • AGM Notice
      • Proceedings
      • Voting Results
      • Transcript of the AGM
    • IEPF
      • Unclaimed Dividend
      • Nodal Officer
    • Analyst/ Investors
      • Presentation
      • Audio / Video Recording
      • Transcript
    • Shareowner Services
      • FAQ
      • Green Initiative
      • Investor Contact
      • Other Notices
      • Credit Rating
  • careers
    • Introduction
    • Life@Wockhardt
    • L&D Initiatives
    • Voice of Wockhardians
    • Career@Wockhardt
  • Media
    • Press Releases
    • Wockhardt in Media
  • ESG
  • Contact us

Quick Links

  • Home
  • About Us
  • Investors
  • Careers
  • Media
  • ESG
  • Contact Us
  • Pharmacovigilance – Adverse Event Reporting
  • Privacy Policy
  • Archival Policy
  • Terms and Conditions

Get in Touch

D-4 MIDC, Chikalthana
Chhatrapati Sambhajinagar, 431006, India
91-22-2653 4444
contactus@wockhardt.com
Corporate Identity Number: L24230MH1999PLC120720

Wock Stock

wpChatIcon